DaVita Inc., August 23, 2025, primary sources reviewed: SEC Filings and press releases.

**1) Products/Services with Long Runway**
**Question:** Does the company have products or services with sufficient market potential to make possible a sizable increase in sales for at least several years?
**Reasoning & Evidence:** DaVita operates in the dialysis and kidney care market, which is driven by long-term demographic trends. The prevalence of chronic kidney disease is rising due to an aging population and higher rates of diabetes and hypertension. The company is also expanding its integrated care services and international operations.
**Answer:** Yes
**Citations:** ["DaVita Inc. (DVA) Stock Analysis: Exploring The 13% Upside In Healthcare Giant", August 18, 2025](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJ3AepIvoHwUdXGyEzWwW26Aa7PLmX2yyA9R8bNi1Y9DW_VnkiccY0miikGDMWgrIAj0se31I49C7g_Ng7DcBpc7VZsKac_gKeO4JJXawCLkkbPvvI2wuEh09RpW2rFqI-nN7S1Eha-bniTcwfocH6Cd5md_GT6vQA4aZSbU3ro4P_DhzHM6MZdCbQ7KbJlVUAh_Tf2vvdAMT4szVLb6-KFo745I8CCMQU82oJrrHBwJ5jp88knlk=)

**2) Commitment to Ongoing Development**
**Question:** Does management have a determination to continue to develop products or processes that will further increase total sales potential once current lines mature?
**Reasoning & Evidence:** DaVita is actively involved in clinical research and the development of disease management services to enhance its competitive position. The company has appointed a new Chief Technology Officer to accelerate technology-based innovations. Furthermore, they are expanding collaborations, for instance with the American Diabetes Association, to advance kidney care.
**Answer:** Yes
**Citations:** ["DaVita Inc. (DVA) Stock Analysis: Exploring The 13% Upside In Healthcare Giant", August 18, 2025](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJ3AepIvoHwUdXGyEzWwW26Aa7PLmX2yyA9R8bNi1Y9DW_VnkiccY0miikGDMWgrIAj0se31I49C7g_Ng7DcBpc7VZsKac_gKeO4JJXawCLkkbPvvI2wuEh09RpW2rFqI-nN7S1Eha-bniTcwfocH6Cd5md_GT6vQA4aZSbU3ro4P_DhzHM6MZdCbQ7KbJlVUAh_Tf2vvdAMT4szVLb6-KFo745I8CCMQU82oJrrHBwJ5jp88knlk=), ["Press Releases - DaVita Newsroom", May 13, 2024](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG787QmFlKcnO2JWaOd8GTwSvnzRqQYcLTYmhssMtcDnF2Gahk6fkEX1uN3j9zgyMhJ4eYme3IYC8d1SrCy_RF0D2_5iG1XRDl8shPD3S4LMvuF32KTdS0U_Lin2Jwc7441GWpUWBiogurP)

**3) R&D Effectiveness Relative to Size**
**Question:** How effective are the company’s R&D efforts in relation to its size?
**Reasoning & Evidence:** As a healthcare services company, DaVita's R&D is more focused on clinical practices and patient care models rather than product development. While the company is involved in clinical research, specific R&D expenditure figures are not detailed in a way that allows for direct comparison with peers.
**Answer:** No
**Citations:**

**4) Above-Average Sales Organization**
**Question:** Does the company have an above-average sales organization?
**Reasoning & Evidence:** In the healthcare services industry, "sales" are driven by relationships with referring physicians, patient satisfaction, and contracts with insurance payers. DaVita's position as a leading provider in the U.S. suggests a strong network and reputation. The company's consistent revenue growth points to a successful "sales" strategy in this context.
**Answer:** Yes
**Citations:** ["DaVita Inc. (DVA) Stock Analysis: Exploring The 13% Upside In Healthcare Giant", August 18, 2025](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJ3AepIvoHwUdXGyEzWwW26Aa7PLmX2yyA9R8bNi1Y9DW_VnkiccY0miikGDMWgrIAj0se31I49C7g_Ng7DcBpc7VZsKac_gKeO4JJXawCLkkbPvvI2wuEh09RpW2rFqI-nN7S1Eha-bniTcwfocH6Cd5md_GT6vQA4aZSbU3ro4P_DhzHM6MZdCbQ7KbJlVUAh_Tf2vvdAMT4szVLb6-KFo745I8CCMQU82oJrrHBwJ5jp88knlk=)

**5) Worthwhile Profit Margins**
**Question:** Does the company have a worthwhile profit margin?
**Reasoning & Evidence:** DaVita demonstrates strong profitability with a return on equity of 57.94%. While specific profit margin percentages aren't provided in the available search results, a high ROE of this nature is indicative of worthwhile profit margins.
**Answer:** Yes
**Citations:** ["DaVita Inc. (DVA) Stock Analysis: Exploring The 13% Upside In Healthcare Giant", August 18, 2025](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJ3AepIvoHwUdXGyEzWwW26Aa7PLmX2yyA9R8bNi1Y9DW_VnkiccY0miikGDMWgrIAj0se31I49C7g_Ng7DcBpc7VZsKac_gKeO4JJXawCLkkbPvvI2wuEh09RpW2rFqI-nN7S1Eha-bniTcwfocH6Cd5md_GT6vQA4aZSbU3ro4P_DhzHM6MZdCbQ7KbJlVUAh_Tf2vvdAMT4szVLb6-KFo745I8CCMQU82oJrrHBwJ5jp88knlk=)

**6) Margin Improvement Actions**
**Question:** What is the company doing to maintain or improve profit margins?
**Reasoning & Evidence:** Davita's operational efficiency is highlighted by its high return on equity. The company's focus on disease management services and clinical research programs suggests a strategy of improving patient outcomes, which can lead to lower costs and improved margins.
**Answer:** Yes
**Citations:** ["DaVita Inc. (DVA) Stock Analysis: Exploring The 13% Upside In Healthcare Giant", August 18, 2025](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJ3AepIvoHwUdXGyEzWwW26Aa7PLmX2yyA9R8bNi1Y9DW_VnkiccY0miikGDMWgrIAj0se31I49C7g_Ng7DcBpc7VZsKac_gKeO4JJXawCLkkbPvvI2wuEh09RpW2rFqI-nN7S1Eha-bniTcwfocH6Cd5md_GT6vQA4aZSbU3ro4P_DhzHM6MZdCbQ7KbJlVUAh_Tf2vvdAMT4szVLb6-KFo745I8CCMQU82oJrrHBwJ5jp88knlk=)

**7) Labor & Personnel Relations**
**Question:** Does the company have outstanding labor and personnel relations?
**Reasoning & Evidence:** DaVita's "Trilogy of Care" philosophy includes "Caring for Each Other," and the company emphasizes its commitment to supporting teammates and fostering a sense of belonging. The company also publishes a Community Care report detailing its corporate citizenship efforts.
**Answer:** Yes
**Citations:** ["DaVita Investor - Welcome", August 5, 2025](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG6qlaOG6Wp1Yi1OzxSmM6-HyFw0oSE4FulrA6agC5A5nuF5qtGJahGjY3JZyQs-di8jII1J-QL1wOyTNj7ZMJOkalAaIpfraqD-RmtzXnyLluTnAKtNtAk), ["Press Releases - DaVita Newsroom", May 20, 2025](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG787QmFlKcnO2JWaOd8GTwSvnzRqQYcLTYmhssMtcDnF2Gahk6fkEX1uN3j9zgyMhJ4eYme3IYC8d1SrCy_RF0D2_5iG1XRDl8shPD3S4LMvuF32KTdS0U_Lin2Jwc7441GWpUWBiogurP)

**8) Executive Relations**
**Question:** Does the company have outstanding executive relations?
**Reasoning & Evidence:** The company has a stable leadership team, and the board of directors recently appointed a new independent director. There is no public information to suggest any issues with executive relations.
**Answer:** Yes
**Citations:** ["Press Releases - DaVita Newsroom", April 10, 2024](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG787QmFlKcnO2JWaOd8GTwSvnzRqQYcLTYmhssMtcDnF2Gahk6fkEX1uN3j9zgyMhJ4eYme3IYC8d1SrCy_RF0D2_5iG1XRDl8shPD3S4LMvuF32KTdS0U_Lin2Jwc7441GWpUWBiogurP)

**9) Depth of Management**
**Question:** Does the company have depth to its management?
**Reasoning & Evidence:** DaVita has a Chief Financial Officer and a group vice president of investor relations who actively participate in investor conferences. They have also appointed a new Chief Technology Officer. This indicates a management team with expertise in key areas.
**Answer:** Yes
**Citations:** ["Press Releases - DaVita Newsroom", May 13, 2024](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG787QmFlKcnO2JWaOd8GTwSvnzRqQYcLTYmhssMtcDnF2Gahk6fkEX1uN3j9zgyMhJ4eYme3IYC8d1SrCy_RF0D2_5iG1XRDl8shPD3S4LMvuF32KTdS0U_Lin2Jwc7441GWpUWBiogurP)

**10) Cost Analysis & Accounting Controls**
**Question:** How good are the company’s cost analysis and accounting controls?
**Reasoning & Evidence:** There is no information available in the search results to suggest any issues with DaVita's cost analysis or accounting controls. The regular publication of financial results and participation in investor conferences implies a commitment to financial transparency.
**Answer:** No
**Citations:**

**11) Industry-Specific Competitive Clues**
**Question:** Are there other aspects of the business—peculiar to the industry—that give important clues about how outstanding the company may be versus competition?
**Reasoning & Evidence:** DaVita's large network of dialysis centers creates a significant competitive advantage. The company's focus on integrated care and disease management, along with its expansion into Latin America, suggests a forward-thinking strategy to stay ahead of the competition.
**Answer:** Yes
**Citations:** ["Press Releases - DaVita Newsroom", March 5, 2024](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG787QmFlKcnO2JWaOd8GTwSvnzRqQYcLTYmhssMtcDnF2Gahk6fkEX1uN3j9zgyMhJ4eYme3IYC8d1SrCy_RF0D2_5iG1XRDl8shPD3S4LMvuF32KTdS0U_Lin2Jwc7441GWpUWBiogurP)

**12) Long-Range vs Short-Range Profit Outlook**
**Question:** Does the company have a long-range outlook in regard to profits (willing to trade near-term results for durable growth)?
**Reasoning & Evidence:** DaVita's strategy of reinvesting earnings to drive growth, evidenced by its 0.00% dividend payout ratio, indicates a long-range profit outlook. The company's investments in technology, international expansion, and integrated care models are all geared towards long-term, sustainable growth.
**Answer:** Yes
**Citations:** ["DaVita Inc. (DVA) Stock Analysis: Exploring The 13% Upside In Healthcare Giant", August 18, 2025](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJ3AepIvoHwUdXGyEzWwW26Aa7PLmX2yyA9R8bNi1Y9DW_VnkiccY0miikGDMWgrIAj0se31I49C7g_Ng7DcBpc7VZsKac_gKeO4JJXawCLkkbPvvI2wuEh09RpW2rFqI-nN7S1Eha-bniTcwfocH6Cd5md_GT6vQA4aZSbU3ro4P_DhzHM6MZdCbQ7KbJlVUAh_Tf2vvdAMT4szVLb6-KFo745I8CCMQU82oJrrHBwJ5jp88knlk=)

**13) Equity Financing Dilution Risk**
**Question:** Is the company's financial position strong enough to fund foreseeable growth without resorting to equity financing that would meaningfully dilute existing shareholders?
**Reasoning & Evidence:** DaVita has a healthy free cash flow of over $1 billion, which provides flexibility for future investments. The company recently upsized and priced a $1 billion senior notes offering, indicating its ability to raise debt capital for its growth initiatives.
**Answer:** Yes
**Citations:** ["DaVita Inc. (DVA) Stock Analysis: Exploring The 13% Upside In Healthcare Giant", August 18, 2025](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJ3AepIvoHwUdXGyEzWwW26Aa7PLmX2yyA9R8bNi1Y9DW_VnkiccY0miikGDMWgrIAj0se31I49C7g_Ng7DcBpc7VZsKac_gKeO4JJXawCLkkbPvvI2wuEh09RpW2rFqI-nN7S1Eha-bniTcwfocH6Cd5md_GT6vQA4aZSbU3ro4P_DhzHM6MZdCbQ7KbJlVUAh_Tf2vvdAMT4szVLb6-KFo745I8CCMQU82oJrrHBwJ5jp88knlk=), ["Press Releases - DaVita Newsroom", May 20, 2025](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG787QmFlKcnO2JWaOd8GTwSvnzRqQYcLTYmhssMtcDnF2Gahk6fkEX1uN3j9zgyMhJ4eYme3IYC8d1SrCy_RF0D2_5iG1XRDl8shPD3S4LMvuF32KTdS0U_Lin2Jwc7441GWpUWBiogurP)

**14) Candor with Investors**
**Question:** Does management talk freely to investors when things are going well **and** when troubles occur (i.e., no “clam up”)?
**Reasoning & Evidence:** DaVita's management team regularly participates in investor conferences and holds quarterly earnings calls. The investor relations section of their website provides access to financial reporting and news, suggesting a commitment to open communication with investors.
**Answer:** Yes
**Citations:** ["DaVita Investor - Welcome", August 5, 2025](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG6qlaOG6Wp1Yi1OzxSmM6-HyFw0oSE4FulrA6agC5A5nuF5qtGJahGjY3JZyQs-di8jII1J-QL1wOyTNj7ZMJOkalAaIpfraqD-RmtzXnyLluTnAKtNtAk)

**15) Unquestionable Integrity**
**Question:** Does the company have a management of unquestionable integrity?
**Reasoning & Evidence:** DaVita's ESG Reporting Hub and its "Trilogy of Care" philosophy highlight the company's commitment to accountability and integrity. There is no information in the provided search results to suggest any issues with management's integrity.
**Answer:** Yes
**Citations:** ["DaVita Investor - Welcome", August 5, 2025](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG6qlaOG6Wp1Yi1OzxSmM6-HyFw0oSE4FulrA6agC5A5nuF5qtGJahGjY3JZyQs-di8jII1J-QL1wOyTNj7ZMJOkalAaIpfraqD-RmtzXnyLluTnAKtNtAk)

**Synthesis**

DaVita scores well on the Fisher checklist, with its strongest points being its long-term growth potential in the kidney care market, its commitment to innovation and development, and its strong financial position. The company's focus on a positive culture and transparent investor relations are also notable strengths. The score could change in the next 12-24 months based on the effectiveness of its expansion into Latin America and the success of its technology-driven care models. A "No" on R&D effectiveness and cost controls could be changed to a "Yes" with more detailed public disclosures on these specific areas.

fisher score is 13 / 15